Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Standardized peptidome profiling of human serum for the detection of pancreatic cancer.

Zapico-Muñiz E, Farré-Viladrich A, Rico-Santana N, González-Sastre F, Mora-Brugués J.

Pancreas. 2010 Nov;39(8):1293-8. doi: 10.1097/MPA.0b013e3181dfcbe5.

PMID:
20924310
2.

Genetic mutations in a Spanish population with chronic pancreatitis.

Mora J, Comas L, Ripoll E, Gonçalves P, Queraltó JM, González-Sastre F, Farré A.

Pancreatology. 2009;9(5):644-51. doi: 10.1159/000181177. Epub 2009 Aug 4.

PMID:
19657220
3.

[Polycystic ovary syndrome and cardiovascular risk].

Sesmilo G, Gonzàlez-Sastre F.

Med Clin (Barc). 2007 Sep 8;129(8):297-8. Spanish. No abstract available.

PMID:
17878024
4.

Applicability of alpha-fetoprotein-concanavalin A (AFP-ConA) binding to discriminate between germinal or hepatic origin of AFP in germ cell tumour patients during chemotherapy or follow-up.

Mora J, Garrido A, Antonijuan A, Martínez S, González-Sastre F.

Clin Chem Lab Med. 2007;45(7):932-3. No abstract available.

PMID:
17617043
5.

Dietary phytosterols modulate T-helper immune response but do not induce apparent anti-inflammatory effects in a mouse model of acute, aseptic inflammation.

Calpe-Berdiel L, Escolà-Gil JC, Benítez S, Bancells C, González-Sastre F, Palomer X, Blanco-Vaca F.

Life Sci. 2007 May 1;80(21):1951-6. Epub 2007 Mar 1.

PMID:
17382351
6.

Agreement between K-ras sequence variations detected in plasma and tissue DNA in pancreatic and colorectal cancer.

Mora J, Urgell E, Farré A, Comas L, Montserrat E, González-Sastre F.

Clin Chem. 2006 Jul;52(7):1448-9. No abstract available.

7.

[Determination and utilisation of the plasmatic concentration of homocysteine in clinical practice].

Llevadot J, Blanco Vaca F, González Sastre F.

Med Clin (Barc). 2005 Apr 16;124(14):544-53. Review. Spanish.

PMID:
15847753
8.

Impaired binding affinity of electronegative low-density lipoprotein (LDL) to the LDL receptor is related to nonesterified fatty acids and lysophosphatidylcholine content.

Benítez S, Villegas V, Bancells C, Jorba O, González-Sastre F, Ordóñez-Llanos J, Sánchez-Quesada JL.

Biochemistry. 2004 Dec 21;43(50):15863-72.

PMID:
15595841
9.

Evaluation of two nonisotopic immunoassays for determination of glutamic acid decarboxylase and tyrosine phosphatase autoantibodies in serum.

Palomer X, Mauricio D, Rodríguez-Espinosa J, Zapico E, Mayoral C, González-Sastre F, de Leiva A, Blanco-Vaca F.

Clin Chem. 2004 Aug;50(8):1378-82. Epub 2004 May 20.

10.

Phenytoin treatment reduces atherosclerosis in mice through mechanisms independent of plasma HDL-cholesterol concentration.

Trocho C, Escolà-Gil JC, Ribas V, Benítez S, Martín-Campos JM, Rotllan N, Osaba L, Ordóñez-Llanos J, González-Sastre F, Blanco-Vaca F.

Atherosclerosis. 2004 Jun;174(2):275-85.

PMID:
15136057
11.

Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction.

Benítez S, Sánchez-Quesada JL, Ribas V, Jorba O, Blanco-Vaca F, González-Sastre F, Ordóñez-Llanos J.

Circulation. 2003 Jul 8;108(1):92-6. Epub 2003 Jun 23.

PMID:
12821559
12.

Mechanisms of HDL deficiency in mice overexpressing human apoA-II.

Julve J, Escolà-Gil JC, Ribas V, González-Sastre F, Ordóñez-Llanos J, Sánchez-Quesada JL, Blanco-Vaca F.

J Lipid Res. 2002 Oct;43(10):1734-42.

13.

ApoA-I(MALLORCA) impairs LCAT activation and induces dominant familial hypoalphalipoproteinemia.

Martín-Campos JM, Julve J, Escolà JC, Ordóñez-Llanos J, Gómez J, Binimelis J, González-Sastre F, Blanco-Vaca F.

J Lipid Res. 2002 Jan;43(1):115-23.

14.

[Secular trends in smoking according to educational level between 1986 and 1996: The MONICA study. Catalonia].

Paluzie G, Sans S, Balañà L, Puig T, González-Sastre F, Balaguer-Vintró I.

Gac Sanit. 2001 Jul-Aug;15(4):303-11. Spanish.

15.

ApoA-II expression in CETP transgenic mice increases VLDL production and impairs VLDL clearance.

Escolà-Gil JC, Julve J, Marzal-Casacuberta A, Ordóñez-Llanos J, González-Sastre F, Blanco-Vaca F.

J Lipid Res. 2001 Feb;42(2):241-8.

16.

Which cholesterol are we measuring with the Roche direct, homogeneous LDL-C Plus assay?

Ordóñez-Llanos J, Wägner AM, Bonet-Marqués R, Sánchez-Quesada JL, Blanco-Vaca F, González-Sastre F.

Clin Chem. 2001 Jan;47(1):124-6. No abstract available.

17.

Increased production of very-low-density lipoproteins in transgenic mice overexpressing human apolipoprotein A-II and fed with a high-fat diet.

Julve J, Escolà-Gil JC, Marzal-Casacuberta A, Ordóñez-Llanos J, González-Sastre F, Blanco-Vaca F.

Biochim Biophys Acta. 2000 Nov 15;1488(3):233-44.

PMID:
11082533
18.

Prospective evaluation of the contribution of K-ras mutational analysis and CA 19.9 measurement to cytological diagnosis in patients with clinical suspicion of pancreatic cancer.

Urgell E, Puig P, Boadas J, Capellà G, Queraltó JM, Boluda R, Antonijuan A, Farré A, Lluís F, González-Sastre F, Mora J.

Eur J Cancer. 2000 Oct;36(16):2069-75.

PMID:
11044643
19.

Expression of human apolipoprotein A-II in apolipoprotein E-deficient mice induces features of familial combined hyperlipidemia.

Escolà-Gil JC, Julve J, Marzal-Casacuberta A, Ordóñez-Llanos J, González-Sastre F, Blanco-Vaca F.

J Lipid Res. 2000 Aug;41(8):1328-38.

20.

Comparison of the Abbott IMx and a high-performance liquid chromatography method for measuring total plasma homocysteine.

Blanco-Vaca F, Arcelús R, González-Sastre F, Ordóñez-Llanos J, Queraltó-Compañó JM.

Clin Chem Lab Med. 2000 Apr;38(4):327-9.

PMID:
10928653
21.

Determinants of plasma homocyst(e)ine in patients with nephrotic syndrome.

Joven J, Arcelús R, Camps J, Ordóñez-Llanos J, Vilella E, González-Sastre F, Blanco-Vaca F.

J Mol Med (Berl). 2000;78(3):147-54.

PMID:
10868477
22.

[Glycemia: multi-faceted analytical magnitude].

Zapico Muñiz E, González Sastre F.

Med Clin (Barc). 2000 Apr 29;114(16):619-21. Spanish. No abstract available.

PMID:
10846688
23.

A highly sensitive method for K-ras mutation detection is useful in diagnosis of gastrointestinal cancer.

Puig P, Urgell E, Capellá G, Sancho FJ, Pujol J, Boadas J, Farré A, Lluís F, González-Sastre F, Mora J.

Int J Cancer. 2000 Jan 1;85(1):73-7.

24.

Ascitic fluid interleukin-8 to distinguish spontaneous bacterial peritonitis and sterile ascites in cirrhotic patients.

Martínez-Brú C, Gómez C, Cortés M, Soriano G, Guarner C, Planella T, González-Sastre F.

Clin Chem. 1999 Nov;45(11):2027-8. No abstract available.

25.

Beta 2-microglobulin and immunoglobulins are more useful markers of disease progression in HIV than neopterin and adenosine deaminase.

Martínez-Brú C, Cortés M, Planella T, Barrio J, Cadafalch J, Domingo P, Fuster M, Sambeat MA, González-Sastre F.

Ann Clin Biochem. 1999 Sep;36 ( Pt 5):601-8.

PMID:
10505209
26.

Effect of simvastatin treatment on the electronegative low-density lipoprotein present in patients with heterozygous familial hypercholesterolemia.

Sánchez-Quesada JL, Otal-Entraigas C, Franco M, Jorba O, González-Sastre F, Blanco-Vaca F, Ordóñez-Llanos J.

Am J Cardiol. 1999 Sep 15;84(6):655-9.

PMID:
10498134
27.

Pitfalls of direct HDL-cholesterol measurements in mouse models of hyperlipidemia and atherosclerosis.

Escolà-Gil JC, Jorba O, Julve-Gil J, González-Sastre F, Ordóñez-Llanos J, Blanco-Vaca F.

Clin Chem. 1999 Sep;45(9):1567-9. No abstract available.

28.

Improved detection of K-ras codon 12 mutations in fecal exfoliated cells.

Puig P, Urgell E, Capellá G, Villanueva A, Grau M, Sancho FJ, Pujol J, Lluís F, González-Sastre F, Mora J.

Lab Invest. 1999 May;79(5):617-8. No abstract available.

PMID:
10334573
29.

Free cholesterol deposition in the cornea of human apolipoprotein A-II transgenic mice with functional lecithin: cholesterol acyltransferase deficiency.

Julve-Gil J, Ruiz-Pérez E, Casaroli-Marano RP, Marzal-Casacuberta A, Escolà-Gil JC, González-Sastre F, Blanco-Vaca F.

Metabolism. 1999 Apr;48(4):415-21.

PMID:
10206431
30.

K-ras gene mutations in the diagnosis of fine-needle aspirates of pancreatic masses: prospective study using two techniques with different detection limits.

Mora J, Puig P, Boadas J, Urgell E, Montserrat E, Lerma E, González-Sastre F, Lluís F, Farré A, Capellá G.

Clin Chem. 1998 Nov;44(11):2243-8.

31.

Molecular diagnosis of lecithin: cholesterol acyltransferase deficiency in a presymptomatic proband.

Cirera S, Julve J, Ferrer I, Mainou C, Bonet R, Martin-Campos JM, González-Sastre F, Blanco-Vaca F.

Clin Chem Lab Med. 1998 Jun;36(7):443-8.

PMID:
9746267
32.

Ascorbic acid inhibits the increase in low-density lipoprotein (LDL) susceptibility to oxidation and the proportion of electronegative LDL induced by intense aerobic exercise.

Sánchez-Quesada JL, Jorba O, Payés A, Otal C, Serra-Grima R, González-Sastre F, Ordóñez-Llanos J.

Coron Artery Dis. 1998;9(5):249-55.

PMID:
9710684
33.

Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease?

Chico A, Pérez A, Córdoba A, Arcelús R, Carreras G, de Leiva A, González-Sastre F, Blanco-Vaca F.

Diabetologia. 1998 Jun;41(6):684-93.

PMID:
9662051
34.

The predictive value of several markers in the progression to acquired immunodeficiency syndrome.

Planella T, Cortés M, Martínez-Brú C, Barrio J, Sambeat MA, González-Sastre F.

Clin Chem Lab Med. 1998 Mar;36(3):169-73.

PMID:
9589805
35.

Human apolipoprotein A-II is a pro-atherogenic molecule when it is expressed in transgenic mice at a level similar to that in humans: evidence of a potentially relevant species-specific interaction with diet.

Escolà-Gil JC, Marzal-Casacuberta A, Julve-Gil J, Ishida BY, Ordóñez-Llanos J, Chan L, González-Sastre F, Blanco-Vaca F.

J Lipid Res. 1998 Feb;39(2):457-62.

36.

[Hyperhomocysteinemia: a new marker of vascular risk: affected vascular areas, its role in the pathogenesis of arteriosclerosis and thrombosis and treatment].

Córdoba Porras A, Blanco Vaca F, González Sastre F.

Med Clin (Barc). 1997 Nov 22;109(18):715-25. Review. Spanish. No abstract available.

PMID:
9499150
37.

LDL from aerobically-trained subjects shows higher resistance to oxidative modification than LDL from sedentary subjects.

Sánchez-Quesada JL, Ortega H, Payés-Romero A, Serrat-Serrat J, González-Sastre F, Lasunción MA, Ordóñez-Llanos J.

Atherosclerosis. 1997 Jul 25;132(2):207-13.

PMID:
9242966
38.

Calculation of LDL-cholesterol by using apolipoprotein B for classification of nonchylomicronemic dyslipemia.

Planella T, Cortés M, Martínez-Brú C, González-Sastre F, Ordóñez-Llanos J.

Clin Chem. 1997 May;43(5):808-15.

39.

Susceptibility of plasma low- and high-density lipoproteins to oxidation in patients with severe hyperhomocysteinemia.

Córdoba-Porras A, Sánchez-Quesada JL, González-Sastre F, Ordóñez-Llanos J, Blanco-Vaca F.

J Mol Med (Berl). 1996 Dec;74(12):771-6.

PMID:
8974018
40.

Electronegative low density lipoprotein subform is increased in patients with short-duration IDDM and is closely related to glycaemic control.

Sánchez-Quesada JL, Pérez A, Caixàs A, Ordónmez-Llanos J, Carreras G, Payés A, González-Sastre F, de Leiva A.

Diabetologia. 1996 Dec;39(12):1469-76.

PMID:
8960828
41.

Brain pyruvate oxidation in experimental thiamin-deficiency encephalopathy.

Munujos P, Coll-Cantí J, Beleta J, González-Sastre F, Gella FJ.

Clin Chim Acta. 1996 Nov 15;255(1):13-25.

PMID:
8930410
42.

Different hCG assays to measure ectopic hCG secretion in bladder carcinoma patients.

Mora J, Gascón N, Tabernero JM, Rodríguez-Espinosa J, González-Sastre F.

Br J Cancer. 1996 Oct;74(7):1081-4.

43.

Functional lecithin:cholesterol acyltransferase deficiency and high density lipoprotein deficiency in transgenic mice overexpressing human apolipoprotein A-II.

Marzal-Casacuberta A, Blanco-Vaca F, Ishida BY, Julve-Gil J, Shen J, Calvet-Márquez S, González-Sastre F, Chan L.

J Biol Chem. 1996 Mar 22;271(12):6720-8.

44.

Increase of LDL susceptibility to oxidation occurring after intense, long duration aerobic exercise.

Sánchez-Quesada JL, Homs-Serradesanferm R, Serrat-Serrat J, Serra-Grima JR, González-Sastre F, Ordóñez-Llanos J.

Atherosclerosis. 1995 Dec;118(2):297-305.

PMID:
8770323
45.

In vitro effect of dipyrone on several peroxidase labelled immunoassays.

Gascón-Roche N, Mora-Brugués J, Rodriguez-Espinosa J, Cortés-Rius M, González-Sastre F.

Eur J Clin Chem Clin Biochem. 1995 Apr;33(4):221-4.

PMID:
7542931
46.

Triglyceride-rich lipoprotein abnormalities in CAPD-treated patients.

Llopart R, Doñate T, Oliva JA, Rodá M, Rousaud F, Gonzalez-Sastre F, Pedreño J, Ordoñez-Llanos J.

Nephrol Dial Transplant. 1995;10(4):537-40.

PMID:
7623998
47.

Diagnostic specificity of creatine kinase-MB isoenzyme in physically active subjects.

Ordóñez-Llanos J, Serra-Grima R, González-Sastre F.

Circulation. 1994 Mar;89(3):1447-8. No abstract available.

PMID:
8124828
48.

Platelet LDL receptor recognizes with the same apparent affinity both oxidized and native LDL. Evidence that the receptor-ligand complexes are not internalized.

Pedreño J, de Castellarnau C, Cullaré C, Ortín R, Sánchez JL, Llopart R, González-Sastre F.

Arterioscler Thromb. 1994 Mar;14(3):401-8.

PMID:
8123645
49.

Evaluation of Ciba Corning ACS:180 automated immunoassay system.

Mora-Brugués J, Gascón-Roche N, Rodríguez-Espinosa J, Cortés-Rius M, González-Sastre F.

Clin Chem. 1994 Mar;40(3):407-10.

50.

[Comparison of two serum alpha-fetoprotein assays: Amerlite AFP and AFP-2T].

Mora-Brugués J, Gascón-Roche N, Rodríguez-Espinosa J, González-Sastre F.

Ann Biol Clin (Paris). 1994;52(6):467-8. French. No abstract available.

PMID:
7531961

Supplemental Content

Loading ...
Support Center